Glenn serves on the Apollomics Board as an independent director since March 2023. Glenn’s career spans more than 20 years of financial and commercial experience in the life sciences industry. Currently Glenn is the Chief Financial Officer (CFO) at Inversago. Prior to that, he was the CFO of Evaxion Biotech A/S, an AI enabled immuno-oncology company and led the company through a successful IPO on Nasdaq in February 2021, and successfully raised follow-on capital later that same year. He has also served as the Chief Financial Officer of electroCore, Inc. and was a key member of the management team that led the company through a successful IPO on Nasdaq in June 2018. Additionally, Glenn served as an executive in various innovative healthcare and technology companies including GE Capital, where he served as Executive Vice President.

Glenn received an Electronic Engineering Technology degree and a Managerial MBA in Finance from the Rutgers University Center for Management Development.